Trials / Terminated
TerminatedNCT00989092
Darbepoetin Alfa and Anemia of Cancer
A Randomized, Open-label, Comparative Study to Estimate the Effect of Darbepoetin Alfa on Hospital Days, Economic Outcomes, and Health-related Quality of Life in Subjects With Nonmyeloid Malignancies and Anemia of Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 287 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase 2, multicenter, randomized, open-label, comparative study was designed to determine the effect of darbepoetin alfa on hospital days, economic outcomes, and health related quality of life (HRQOL) in anemic patients with nonmyeloid malignancies who were not receiving chemotherapy. Participants were randomly assigned in a 4:1 allocation ratio to receive either 21 weeks of darbepoetin alfa treatment (treatment group) or 12 weeks of observation followed by up to 9 weeks of darbepoetin alfa treatment (observation group).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | darbepoetin alfa | Administered subcutaneously. |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2004-01-01
- Completion
- 2004-06-01
- First posted
- 2009-10-02
- Last updated
- 2014-01-29
- Results posted
- 2014-01-29
Source: ClinicalTrials.gov record NCT00989092. Inclusion in this directory is not an endorsement.